Magnus Ingelman-Sundberg

Magnus Ingelman-Sundberg

Professor, Senior
Telefon: +46852487735
Besöksadress: Solnavägen 9, Biomedicum B5, 17165 Solna
Postadress: C3 Fysiologi och farmakologi, C3 FyFa Farmakogenetik, 171 77 Stockholm

Om mig

  • Professor i molekylär toxikologi sedan 1996, sedan 2006 vid sektionen för farmakogenetik på Institutionen för fysiologi och farmakologi. Senior professor sedan 2025-01-01.

    Tidigare anställningar vid KI omfattar forskarassistent i fysiologisk kemi 1976-1977; lektor i fysiologisk kemi 1977-1987 (formellt anställd 1982); och tf professor i fysiologisk kemi 1987-1995. Nu sektionschef vid Institutionen för fysiologi och farmakologi. Leder en forskargrupp om cirka 7-8 personer. Forskningen är inriktad på genetiska faktorer av betydelse för interindividuella skillnader i läkemedelseffekter och biverkningar samt studier i ett nytt 3D system rörande mekanismer för läkemedelsutlösta biverkningar och enzyminduktion i lever samt mekanismer för uppkomst och behandling av leversjukdomar.

    Utbildning
    Civilingenjör, KungligaTekniska Högskolan, Stockholm, 1975
    Tekn Dr i fysiologisk kemi 1975
    Docent i fysiologisk kemi 1977
    Med kand Karolinska Institutet 1978.

    Akademiska priser och utmärkelser
    Mer än 520 originalarbeten, 38, 961 citeringar (WoS), 62, 092 i Google Scholar), och H-faktor = 101 (ISI) eller 134 (Google Scholar).). Ledamot av Nobelförsamlingen vid Karolinska Institutet 2008-2018. Medlem i Editorial Advisory Boards i t.ex. Trends Pharmacol Sci, Pharmacogenetics and Genomics, Pharmacogenomics, Drug Metabolism Reviews, Drug Metabolism and Disposition, Human Genomics. Ordförande i International Advisory Board of Microsomes and Drug Oxidations 2004-20229. Rankad som en av världens mest inflytelserika forskare (http://sciencewatch.com/sites/sw/files/sw-article/media/worlds-most-inf…) som bygger på citeringar från högt rankade tidskrifter. HIghly cited from Clarivate 2014-2017 coh 2021. Forskningsgruppen rankad outstanding i Karolinska Institutets externa utvärdering External Research Assessment (ERA) 2010. ERC Advanced grant (AdG) för 2017-2022.

    Huvudhandledare till doktorsexamen för 33 doktorander, postdoc-utbildning för 34 doktorer. Priser inkluderar The Svedberg Pris, (Svenska föreningen för biokemi och molekylärbiologi) 1989; hedersmedlem i American Society for Biochemistry and Molecular Biology 1990; The Gerhard B Zbinden Föreläsning Award, EUROTOX 1996; The ISSX European Scientific Achievement Award 2003; Bengt Danielsson-priset, Swedish Academy of Pharmaceutical Sciences 2008; The John G Warner Pfizer lecture award in Pharmaceutical Sciences, University of Michigan, USA 2011, 2918 BCPT Nordic Prize in Basic and Clinical Pharmacology and Toxicology. The 2022 R.T. Williams Distinguished Scientific Achievement Award

    Övrigt:
    Linjenämnden för läkarutbildning : Ordf för studieplanekommitten 3 år, ansvarig för den nya KI 90 GUL studieplan för läkarutbildingen, ledamot 5 år. Docenturnämnden 6 år, ordförande i KIRT 6 år, ordförande för kommittén för valfria perioder i MD läroplan 6 år. Vice ordförande rekryteringsutskottet 3 år, ordförande i rekryteringsutskottet 6 år (till mars 2014) och prodekan (vice dekanus) för rekrytering 2 år. Ordförande i beredningsgrupp vid Naturvetenskapliga forskningsrådet 3 år, medlem i beredningsgrupper vid Naturvetenskapliga forskningsrådet i 6 år, Medicinska forskningsrådet i 6 år, och Norska Forskningsrådet i 6 år.Pedagogiska priser: Mäster 1978, medicinska föreningen; KIs pedagogiska pris 2000. Medlem i Nobelförsamlingen Karolinska Institutet 2008-2018.

Forskningsbeskrivning

  • Nya in vitro-system har utvecklats som kan förutsäga metabolism och levertoxicitet av läkemedel. Nya genetiska faktorer har identifierats som kan utgöra farmakogenomiska biomarkörer för individualisering av läkemedelsbehandling. Rollen av mutationer för individualiserad läkemedelsterapi undersökes. I leverorganoidsystem med bibehållen leverfenotyp studeras mekanismer och behandling av leversjukdomar såsom steatos, fibros, och hepatit.

    Current funding as PI

    • Hjärnfonden 2023-2026
    • ERC PoC 2023-2025
    • Vetenskapsrådet 2022-2024
    • Novartis 2024-2026

Undervisning

  • Har undervisat läkarstudenter sedan 1977 i fysiologisk kemi och basal farmakologi.

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Southern and Eastern Norway Regional Health Authority
    1 January 2022
    Biomarkers for tolerability of clozapine and risk of treatment discontinuation in patients with therapy-resistant schizophrenia<br/><br/>NOResearch stay abroadClozapine (Leponex) is the drug with the best effect in the treatment of schizophrenia. However, the risk of serious side effects limits its use. It is desirable to identify biomarkers that reflect the tolerability of the drug so that it can be used by more patients.Schizophrenia is the most serious of all mental disorders and normally requires lifelong drug treatment. Clozapine has the best clinical effect in the treatment of schizophrenia, but is also associated with an increased risk of agranulocytosis, a very serious side effect that places restrictions on its prescription. Current knowledge indicates that the mechanism behind clozapine-induced toxicity against granulocytes is linked to immunological reactions. To trigger an immunological reaction, a ‘substrate’ is required. Our hypothesis is that one or more breakdown products (metabolites) of clozapine represent ‘substrate(s)’ for such a reaction. <br/><br/>Clozapine has a complicated metabolism. Among these metabolites are so-called nitrenium ions, which are chemically very reactive substances. They bind to all types of proteins, including proteins in granulocytes. These metabolites are difficult to analyze in blood samples, precisely because they bind (covalently) to proteins in various cells. However, the body has a type of enzymes that can deactivate/capture the metabolites 'before they have time' to bind to proteins. These metabolites are quickly converted further into so-called cysteine metabolites, which are stable substances, and can thus be analyzed in blood samples. By analyzing the concentration of cysteine metabolites of clozapine in serum samples, one can thus get a picture of how much of the reactive nitrenium ions is formed.<br/><br/>The project has established a unique analysis method for measuring the level of cysteinyl metabolites in serum samples. The method is based on advanced chromatography coupled to a high-resolution mass spectrometer, which can analyze molecules with an exact mass. In total, the method can analyze the concentration/level of three cysteine metabolites of clozapine. Over the past year, the PhD fellow in the project has analyzed complete metabolite profiles of clozapine in 582 patients and compared levels of the different metabolites in relation to the genotype of "nuclear factor 1 B (NFIB)", which we have previously discovered regulates the activity of metabolizing enzymes. The results of the study show that patients who have the NFIB variant (approximately 10% of the population) have twice as high a concentration of the metabolites N-desmethylclozapine-cysteinyl, which probably reflects that these patients form more of the toxic metabolites and therefore have an increased risk of side effects and reduced tolerability of clozapine. However, these results must be verified in studies where there is better access to clinical data that reflect tolerability. We are already working on a study that will investigate both genotypes and levels of toxic metabolites in patients who terminate clozapine treatment (the hypothesis is increased prevalence of the NFIB variant and/or levels of cysteinyl metabolites in patients who terminate treatment). It is also planned to study the extent to which combination treatment with fluvoxamine, an antidepressant drug, affects the formation of cysteinyl metabolites. The hypothesis in the latter study is that fluvoxamine reduces the formation of toxic metabolites, since combination treatment with fluvoxamine is associated with better tolerability of clozapine. <br/><br/>A manuscript describing the formation of clozapine metabolites in relation to NFIB genotype has been submitted for publication, and is currently "under review" in the journal Drug Metabolism and Disposition. This article will be published in 2025. The ambition is also to publish one or both of the other substudies described above during 2025.<br/>
  • Swedish Research Council
    1 December 2021 - 31 December 2024
  • Southern and Eastern Norway Regional Health Authority
    1 January 2020 - 31 December 2023
  • A novel regimen for treatment of colon cancer using CYP2W1 as a tumor selective target
    Novo Nordisk Foundation
    1 January 2019 - 31 December 2021
  • CYP2W1 as a prognostic marker and target for pharmacological treatment of colon and liver cancer
    Swedish Cancer Society
    1 January 2018
    Each year, approximately 4,100 people receive colon cancer in Sweden and 500 people have liver cancer. If the cancer spreads after surgical treatment, chemotherapy is needed. We have found an enzyme (CYP2W1) that is specifically only found in colon cancer cells and liver cancer cells as well as in some other tumor forms but not in normal tissue. We find this enzyme in higher amounts in liver metastases is in primary colon tumor. We have also developed chemical compounds which by reacting by the enzyme form reactive products that kill the tumor cells. If we treat mice that have a human colon tumor containing CYP2W1 with these compounds, the tumor cannot grow. The project aims to develop even better compounds that are substrates for CYP2W1, to investigate in which other tumor forms the enzyme exists where one can imagine a similar treatment. We will investigate whether CYP2W1 mRNA and peptides from CYP2W1 and deethylated DNA fragments from CYP2W1 genes can serve as new markers for the presence of colon cancer and other human tumors. Furthermore, we want to determine the enzyme structure to produce even better cancer drugs, identify the electron donors to the enzyme needed and see how the enzyme is regulated in tumor cells to find other drugs that upregulate the expression of the enzyme in the tumors. We hope through the project to be able to identify a completely new specific biomarker for colon cancer and liver cancer and to be able to start clinical trials with the substances we identified for a principally new way of treating colon cancer and other cancer.
  • Southern and Eastern Norway Regional Health Authority
    1 January 2018 - 31 December 2022
  • CYP2W1 as a prognostic marker and target for pharmacological treatment of colon and liver cancer
    Swedish Cancer Society
    1 January 2017
    Each year, approximately 4,100 people receive colon cancer in Sweden and 500 people have liver cancer. If the cancer spreads after surgical treatment, chemotherapy is needed. We have found an enzyme (CYP2W1) that is specifically only found in colon cancer cells and liver cancer cells as well as in some other tumor forms but not in normal tissue. We find this enzyme in higher amounts in liver metastases is in primary colon tumor. We have also developed chemical compounds which by reacting by the enzyme form reactive products that kill the tumor cells. If we treat mice that have a human colon tumor containing CYP2W1 with these compounds, the tumor cannot grow. The project aims to develop even better compounds that are substrates for CYP2W1, to investigate in which other tumor forms the enzyme exists where one can imagine a similar treatment. We will investigate whether CYP2W1 mRNA and peptides from CYP2W1 and deethylated DNA fragments from CYP2W1 genes can serve as new markers for the presence of colon cancer and other human tumors. Furthermore, we want to determine the enzyme structure to produce even better cancer drugs, identify the electron donors to the enzyme needed and see how the enzyme is regulated in tumor cells to find other drugs that upregulate the expression of the enzyme in the tumors. We hope through the project to be able to identify a completely new specific biomarker for colon cancer and liver cancer and to be able to start clinical trials with the substances we identified for a principally new way of treating colon cancer and other cancer.
  • New methods of treating colon cancer and other cancers by using CYP2W1 as a target for drug activation
    Swedish Cancer Society
    1 January 2016
    Each year, approximately 4,100 people receive colon cancer in Sweden. If the cancer spreads after surgical treatment, chemotherapy is needed. We have found an enzyme (CYP2W1) that is specifically only found in colon cancer cells and in some other tumor forms but not in normal tissue. We find this enzyme in higher amounts in liver metastases. We have also developed chemical compounds which by reacting by the enzyme form reactive products that kill the tumor cells. If we treat mice that have a human colon tumor containing CYP2W1 with these compounds, the tumor cannot grow. The project aims to develop even better compounds that are substrates for CYP2W1, to investigate in which other tumor forms the enzyme exists where one can envisage a similar treatment, to use mRNA and peptides from CYP2W1 gene expression as a new marker for the presence of colon cancer and other tumors in humans. Furthermore, we want to determine the enzyme structure to produce even better cancer drugs, identify the electron donors to the enzyme needed and see how the enzyme is regulated in tumor cells to find other drugs that upregulate the expression of the enzyme in the tumors. We hope through the project to be able to identify a completely new specific biomarker for colon cancer and some other tumor forms and to be able to start clinical trials with the substances we identified for a principally new way of treating colon cancer and other cancer.
  • Swedish Research Council
    1 January 2016 - 31 December 2016
  • New methods of treating colon cancer and other cancers by using CYP2W1 as a target for drug activation
    Swedish Cancer Society
    1 January 2015
    Each year, approximately 4,100 people receive colon cancer in Sweden. If the cancer spreads after surgical treatment, chemotherapy is needed. We have found an enzyme (CYP2W1) that is specifically only found in colon cancer cells and in some other tumor forms but not in normal tissue. We find this enzyme in higher amounts in liver metastases. We have also developed chemical compounds which by reacting by the enzyme form reactive products that kill the tumor cells. If we treat mice that have a human colon tumor containing CYP2W1 with these compounds, the tumor cannot grow. The project aims to develop even better compounds that are substrates for CYP2W1, to investigate in which other tumor forms the enzyme exists where one can envisage a similar treatment, to use mRNA and peptides from CYP2W1 gene expression as a new marker for the presence of colon cancer and other tumors in humans. Furthermore, we want to determine the enzyme structure to produce even better cancer drugs, identify the electron donors to the enzyme needed and see how the enzyme is regulated in tumor cells to find other drugs that upregulate the expression of the enzyme in the tumors. We hope through the project to be able to identify a completely new specific biomarker for colon cancer and some other tumor forms and to be able to start clinical trials with the substances we identified for a principally new way of treating colon cancer and other cancer.
  • New methods of treating colon cancer and other cancers by using CYP2W1 as a target for drug activation
    Swedish Cancer Society
    1 January 2014
    Each year, approximately 4,100 people receive colon cancer in Sweden. If the cancer spreads after surgical treatment, chemotherapy is needed. We have found an enzyme (CYP2W1) that is specifically only found in colon cancer cells and in some other tumor forms but not in normal tissue. We find this enzyme in higher amounts in liver metastases. We have also developed chemical compounds which by reacting by the enzyme form reactive products that kill the tumor cells. If we treat mice that have a human colon tumor containing CYP2W1 with these compounds, the tumor cannot grow. The project aims to develop even better compounds that are substrates for CYP2W1, to investigate in which other tumor forms the enzyme exists where one can envisage a similar treatment, to use mRNA and peptides from CYP2W1 gene expression as a new marker for the presence of colon cancer and other tumors in humans. Furthermore, we want to determine the enzyme structure to produce even better cancer drugs, identify the electron donors to the enzyme needed and see how the enzyme is regulated in tumor cells to find other drugs that upregulate the expression of the enzyme in the tumors. We hope through the project to be able to identify a completely new specific biomarker for colon cancer and some other tumor forms and to be able to start clinical trials with the substances we identified for a principally new way of treating colon cancer and other cancer.
  • ERA-NET NEURON Mental Disorders RDmaria aDBS
    Swedish Research Council
    1 January 2014 - 31 December 2016
  • VINNOVA
    1 November 2013 - 31 October 2015
  • Swedish Research Council
    1 January 2011 - 31 December 2015
  • VINNOVA
    1 March 2009 - 30 October 2009
  • Swedish Research Council
    1 January 2009 - 31 December 2011
  • Swedish Research Council for Environment Agricultural Sciences and Spatial Planning
    20 November 2008 - 31 December 2008
  • VINNOVA
    15 January 2008 - 15 October 2008
  • Visa fler

Anställningar

  • Professor, Senior, Fysiologi och farmakologi, Karolinska Institutet, 2025-2025
  • Professor, Fysiologi och farmakologi, Karolinska Institutet, 2020-2024

Examina och utbildning

  • Docent, Medicinsk o fysiologisk kemi, Karolinska Institutet, 1977

Nyheter från KI

Kalenderhändelser från KI